AstraZeneca to Invest $50 Billion in US Manufacturing and R&D by 2030

AstraZeneca Intends to Invest in America

Announcement

AstraZeneca plans to invest approximately $50 billion in the United States by around 2030 to manufacture medicines and boost its research and development efforts. The investment will unlock skilled indirect or direct jobs across the region that will fuel growth and introduce next-generation drugs for American and global patients. The groundwork of this investment is the US’s billion-dollar manufacturing services, which produce medicinal substances for the company’s metabolic portfolio and weight management, also consisting of merged small molecule products, oral GLP-1, oral PCSK9, and baxdrostat. The state will produce peptides, oligonucleotides, and small molecules. The billion-dollar capital investment is an addition to its last year's November 2024 investment of $3.5 billion.

Plans

The medicinal substance facility will be planned in the Commonwealth of Virginia, which will be considered as AstraZeneca’s biggest single manufacturing investment globally. The facility will accelerate data analytics, AI, and automation to streamline production. The investment of $50 billion in our manufacturing and R&D in the next five years in the us consists of continuity in manufacturing that will lead to expansion in Mount Vernon, Indiana. The investment also includes new sites for clinical trials, specialty manufacturing in Coppell, Texas, an R&D facility in Gaithersburg, Maryland, and manufacturing facilities for cell therapy in Maryland, Tarzana, Rockville, and California. It will also expand with its state-of-the-art center in Kendall Square, Massachusetts, and Cambridge. Overall, these planned investments are one of AstraZeneca’s ambitions of reaching $80 billion of total revenue by 2030, from which 50% would be from the US.

Views and Statements

The US Secretary of Commerce Howard Lutnick said, “For many years, Americans have been highly dependent on foreign supply of main pharmaceutical products. Our nation’s new tariff policies and President Trump are concentrating on putting an end to structural deficits. We feel that AstraZeneca’s decision to land substantial pharmaceutical production in our region. This investment has also unlocked many jobs for us, and we promise that the medicines sold in our country will be produced here itself.”

Commonwealth of Virginia, Governor Glenn Youngkin, said, “I’m thankful to AstraZeneca for considering Virginia as the foundation for this transitional investment in the us. This project will raise the bar for the recent technological advancements in pharmaceutical manufacturing.”

Chief executive officer of AstraZeneca, Pascal Soriot, said, “The announcement frames our trust in America’s innovation skills in biopharmaceuticals and also the commitment to providing medicines to millions of patients in America and globally.”